Gland Pharma Limited (NSE: GLAND, BSE: 543245) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹53,843 Cr, it ranks #198 by market cap among the 6,197 Indian listed companies on FinBizNet, and #11 of 86 in Medicinal Chemicals and Botanical Products. At ₹3,340.00 (as of 16 Nov 2026), the share price is 1.0% below its 52-week high of ₹3,374.00 and 112.3% above its 52-week low of ₹1,573.60. The share price is up 75.6% over one year and up 12.4% over three months.
| Current Price | ₹3,340.00 |
|---|---|
| Market Cap | ₹53,843 Cr |
| NSE Symbol | GLAND |
| BSE Code | 543245 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 53.1 |
| Return on Equity | 10.53% |
| Return on Assets | 6.27% |
| 52-Week Range | ₹1,573.60 – ₹3,374.00 |
| 1-Year Price Change | +75.6% |
| 3-Month Price Change | +12.4% |
| Beta (1Y) | 0.44 |
| Dividend Yield | 0.60% |
| Headquarters | Hyderabad, Telangana |
| Website | www.glandpharma.com |
| Revenue | ₹1,834 Cr |
|---|---|
| Net Profit | ₹291 Cr |
| Net Margin | 15.9% |
| EPS (Basic) | ₹17.62 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Gland Pharma Limited reported revenue of ₹1,834 Cr in Q2 FY27, up 23.3% from ₹1,487 Cr in Q2 FY26 and up 1.9% from ₹1,800 Cr in Q1 FY27. It posted a net profit of ₹291 Cr for the quarter, against a net profit of ₹184 Cr in Q2 FY26 (up 58.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,425 Cr (Q4 FY25) to ₹1,834 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹1,834 Cr | ₹291 Cr | 15.9% |
| Q1 FY27 | ₹1,800 Cr | ₹317 Cr | 17.6% |
| Q4 FY26 | ₹1,743 Cr | ₹367 Cr | 21.0% |
| Q3 FY26 | ₹1,695 Cr | ₹261 Cr | 15.4% |
| Q2 FY26 | ₹1,487 Cr | ₹184 Cr | 12.4% |
| Q1 FY26 | ₹1,506 Cr | ₹215 Cr | 14.3% |
| Q4 FY25 | ₹1,425 Cr | ₹187 Cr | 13.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 45.75% of Gland Pharma Limited's shares as of Sept 2026, against 51.83% in Sept 2025 (−6.08 percentage points). Delivery averaged 56.6% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma
1. Pharmaceuticals-This segment manufactures generic injectables.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Gland Pharma Limited | ₹53,843 Cr | 53.1 | 10.53% | ₹1,834 Cr | +75.6% |
Listed by market capitalisation. Ratios are shown for context only.
Gland Pharma Limited is trading at ₹3,340.00, with a market capitalisation of ₹53,843 Cr.
Gland Pharma Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Gland Pharma Limited has a P/E of 53.1 and a return on equity of 10.53%.
Gland Pharma Limited is listed on the NSE under the symbol GLAND and on the BSE under the scrip code 543245.
Gland Pharma Limited's share price is up 75.6% over one year and up 12.4% over three months. Its 52-week range is ₹1,573.60 to ₹3,374.00.
In Q2 FY27, Gland Pharma Limited reported revenue of ₹1,834 Cr and net profit of ₹291 Cr, with basic EPS of ₹17.62 (consolidated, parsed from the company's exchange filing).
Gland Pharma Limited reported revenue of ₹1,834 Cr in Q2 FY27, up 23.3% from ₹1,487 Cr in Q2 FY26 and up 1.9% from ₹1,800 Cr in Q1 FY27.
Promoters held 45.75% of Gland Pharma Limited's shares as of Sept 2026, against 51.83% in Sept 2025 (−6.08 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.